Recursion Pharmaceuticals, Inc. (RXRX) Stock
Key stats
- Market cap
- $2.24B
- Price / Earnings ratio
- -4.6x
- EPS (TTM)
- -$0.86
- Volume
- Loading
- 52-week high
- $5.24
- 52-week low
- $2.77
Source: third-party data provider, as of November 13, 2026
Compare with RXRX
Recent news

What Recursion Pharmaceuticals (RXRX) Said on Its Q3 Earnings Call
What Recursion Pharmaceuticals (RXRX) Said on Its Q3 Earnings Call
RXRX

Recursion's Q3 Earnings Beat Estimates on Sanofi Milestone Revenues
Recursion's Q3 Earnings Beat Estimates on Sanofi Milestone Revenues
RXRX

Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Tops Revenue Estimates
Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Tops Revenue Estimates
RXRX

1 Big Winner and 1 Loser From the Upcoming Anthropic IPO
1 Big Winner and 1 Loser From the Upcoming Anthropic IPO
RXRX
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 46.09
- MACD 12/26/9
- -0.06
- EMA 9 of MACD
- -0.02
- MACD histogram
- -0.04
- SMA 50
- $3.79
- Price below SMA 50
- EMA 50
- $3.74
- Price below EMA 50
- SMA 200
- $3.49
- Price above SMA 200
- EMA 200
- $3.71
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$0.14 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

What Recursion Pharmaceuticals (RXRX) Said on Its Q3 Earnings Call
What Recursion Pharmaceuticals (RXRX) Said on Its Q3 Earnings Call
RXRX

Recursion's Q3 Earnings Beat Estimates on Sanofi Milestone Revenues
Recursion's Q3 Earnings Beat Estimates on Sanofi Milestone Revenues
RXRX

Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Tops Revenue Estimates
Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Tops Revenue Estimates
RXRX

1 Big Winner and 1 Loser From the Upcoming Anthropic IPO
1 Big Winner and 1 Loser From the Upcoming Anthropic IPO
RXRX

Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for Investors
Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for Investors
RXRX

Recursion Pharmaceuticals to Report Q3 Earnings: What's in the Cards?
Recursion Pharmaceuticals to Report Q3 Earnings: What's in the Cards?
RXRX

Recursion Pharmaceuticals (RXRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Recursion Pharmaceuticals (RXRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
RXRX

Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
RXRX

Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider
Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider
RXRX

Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing
Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing
RXRX
News tone: automated (AI) classification of the article's content, not a price prediction.
About Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Najat Khan Ph.D. | CEO, President & Director | 1984 |
| Mr. Ben R. Taylor | CFO & President of Recursion UK | 1977 |
| Mr. Benjamin Mabey M.S. | Chief Technology Officer | 1983 |
| Dr. David Hallett Ph.D. | Chief Scientific Officer | 1969 |
| Mr. Nathan Hatfield J.D., M.B.A. | Chief Legal Officer & Corporate Secretary | — |
| Mr. Ryan Kelly | Chief Communications Officer | — |
| Ms. Erica Fox | Chief People and Impact Officer | — |
| Mr. Matthew Kinn M.B.A. | Chief Business Officer | — |
| Mr. Sid Jain | Senior Vice President of Clinical Development & Data Science | — |
| Dr. Vicki L. Goodman M.D. | Chief Medical Officer | 1971 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 46.09
- MACD 12/26/9
- -0.06
- EMA 9 of MACD
- -0.02
- MACD histogram
- -0.04
- SMA 50
- $3.79
- Price below SMA 50
- EMA 50
- $3.74
- Price below EMA 50
- SMA 200
- $3.49
- Price above SMA 200
- EMA 200
- $3.71
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $8.00
- Average
- $8.00
- High
- $8.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +2.0 | -2.0 | ||||||||||
| 2022 | -34.3 | -11.4 | -33.5 | -19.4 | -7.4 | +35.0 | +0.4 | +26.6 | -2.2 | -2.9 | -10.9 | -17.1 |
| 2023 | +10.3 | -4.7 | -16.1 | -30.8 | +83.1 | -14.8 | +91.3 | -37.0 | -16.1 | -26.3 | +34.6 | +33.4 |
| 2024 | -4.7 | +40.9 | -22.2 | -16.5 | -0.7 | -12.7 | +9.9 | -0.8 | +8.6 | +2.4 | +10.5 | -10.8 |
| 2025 | +0.4 | +3.6 | -19.7 | +9.6 | -24.0 | +15.8 | +16.0 | -17.3 | +4.7 | +8.2 | -14.9 | -6.2 |
| 2026 | -0.2 | -12.2 | -15.4 | +13.1 | +5.9 | -3.2 | -18.3 | +6.9 | +24.0 | -1.0 | -6.3 |



